Charles River Laboratories (CRL) Tops Q4 EPS by 4c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Price: $332.89 -5.39%
Financial Fact:
Cost of services provided: 200.12M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Cost of services provided: 200.12M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.39, $0.04 better than the analyst estimate of $2.35. Revenue for the quarter came in at $994.2 million versus the consensus estimate of $987.2 million.
GUIDANCE:
Charles River Laboratories sees FY2026 EPS of $10.70-$11.20, versus the consensus of $10.89.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
